ResearcherUniversity of SaskatchewanActive in the last 2 years

Franco J. Vizeacoumar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6452-5207; OpenAlex author ID A5083732133. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. Co-author DOI 10.3390/curroncol33080452 ↗
Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing Last author DOI 10.64898/2025.12.01.691211 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shahid Ahmed · 2 shared papers, 2025–2026 · strength 0.56
- Paper Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. DOI 10.3390/curroncol33080452 ↗
- Paper Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing DOI 10.64898/2025.12.01.691211 ↗
Ramy Habib · 1 shared paper, 2026 · strength 0.39
- Paper Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. DOI 10.3390/curroncol33080452 ↗
Nicholas Jette · 1 shared paper, 2025 · strength 0.17
- Paper Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing DOI 10.64898/2025.12.01.691211 ↗
He Dong · 1 shared paper, 2025 · strength 0.17
- Paper Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing DOI 10.64898/2025.12.01.691211 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.